Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment

For Further Information Contact: Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment HASBROUCK HEIGHTS, NJ (May 21, 2014) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report new positive data confirming the advantageous si de effect profile of the Company's lead compound NX- 1207. Results from the Brief Male Sexual Function Ques tionnaire (BMSF) in the Company's recently completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no si gnificant effect on reported sexual function score post- treatment. Currently approved drugs for prostate enlargement (BPH or benign prostatic hyperplasia) can produce significant sexual side effects such as impotence, decreased libido, ejaculation disorders, and male breast enlargement. NX- 1207 has been shown not to have these sexual drawbacks in results to date. As well, certain of the approved BPH drugs, including the combination drug therapies, are also associated with an increased risk of high-grade prostate cancer. By contrast, the area of the prostate targeted with NX-1207 treatment showed less prostate cancer progression with less radiation and surgery due to cancer progression as compared to controls in the recent NX03- 0040 trial. Nymox recently announced the completion of its second pivotal Phase 3 trial of NX-1207 for BPH, NX02-0018, and top-line results for its Phase 2 trial of NX-1207 for localized low risk prostate cancer, NX03-0040. NX-1207 is a novel patented drug developed by Nymox that is administered by a urologist in an office setting directly into the zone of the prostate to be treated. The procedure takes only a few minutes, does not require sedation, anesthesia or catheterization, and involves little or no pain or discomfort. NX-1207 successfully completed a series of blinded contro lled multi-center U.S. clinical trials for BPH where a single 2.5 mg dose of NX-1207 was found to produc e at 90 days an average impr ovement in standardized symptom score about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies sh owed evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 5 years or more. BPH is one of the most commonly diagnosed diseases in older men. The condition can have a significant negative impact on a man’s health and quality of life and can lead to acute urinary retention, incontinence and other serious consequences. It is estimated that 50% of men in thei r 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH. More information about Nymox is available at www.nymox.com, email: [email protected], or 800-936-9669. This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such st atements will prove to be accu rate and the actual results and future events could differ materially from management’s current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. ### NEWS RELEASE

The release as fetched from its publisher. nymox.com ↗